MAC30 is highly expressed in several types of tumors including colorectal cancers, however, its clinicopathological and biological significance in colorectal cancers is currently not known. The aim of our study was to investigate MAC30 expression in distant normal mucosa, adjacent normal mucosa, primary tumors and metastases of colorectal cancer, and to determine the relationship between MAC30 expression and clinicopathological and biological variables. MAC30 expression was

more »

... examined in distant normal mucosa (n=54), adjacent normal mucosa (n=123), primary tumors (n=217) and lymph node metastases (n=56) from colorectal cancer patients. MAC30 cytoplasmic expression was increased from distant normal mucosa to primary tumor and to metastasis (p<0.0001-0.04). Furthermore, 40% primary and 37% metastatic tumors showed stronger cytoplasmic expression of MAC30 at the tumor invasive margins compared to inner tumor areas. Strong cytoplasmic expression of MAC30 in the metastasis was related to a poor prognosis (p=0.04). MAC30 cytoplasmic expression was positively related to expression of proliferating cell nuclear antigen (p=0.04), p53 (p=0.04), nucleoporin 88 (p=0.001), legumain (p=0.004) and particularly interesting new cysteine-histidine rich protein (p=0.004). However, MAC30 expression in the nucleus and stroma did not have any clinicopathological and biological significance (p>0.05). In conclusion, MAC30 protein may play a role in development of colorectal cancer, and can be considered as a prognostic factor.